KTN3379: Updated Phase I data

Updated data from 38 patients with advanced solid tumors in the 2-part, open-label, U.S. Phase I KTN3379-CL-001 trial showed that IV KTN3379 every 3 weeks plus Erbitux cetuximab led to a complete res...